Overview

Study To Evaluate The Effect Of Renal Impairment On The Pharmacokinetics Of PF-04991532

Status:
Completed

Trial end date:
2012-02-01

Target enrollment:

Participant gender:

Summary

The primary purpose of this study is to evaluate the pharmacokinetics, safety and tolerability of a single oral dose of PF-04991532 in subjects with renal impairment.

Phase:

Phase 1

Details

Lead Sponsor:

Pfizer

Treatments:

6-(3-cyclopentyl-2-(4-(trifluoromethyl)-1H-imidazol-1-yl)propanamido)nicotinic acid
Niacin
Nicotinic Acids